The mas­ter deal­mak­er is back: David Hung takes the helm at Vivek Ra­maswamy's Ax­o­vant

David Hung earned his spurs as a mas­ter deal­mak­er in biotech, blaz­ing through a string of ma­jor part­ner­ships for good (and bad) drugs be­fore sell­ing Medi­va­tion at auc­tion for a whop­ping $14 bil­lion. Now he’s back, join­ing hands with one of the bright­est fi­nan­cial en­gi­neers in the busi­ness, as CEO of Vivek Ra­maswamy’s Ax­o­vant.

Ra­maswamy turned heads and raised more than a few eye­brows when he snagged a failed Alzheimer’s drug from Glax­o­SmithK­line for $5 mil­lion up­front and then made it the cen­tral fea­ture in a record-set­ting biotech IPO for Ax­o­vant $AX­ON. Since then, Ra­maswamy has been wheel­ing and deal­ing him­self, set­ting up more com­pa­nies as well as an­oth­er IPO for My­ovant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA